The Mayo Clinic Center for Individualized Treatment of Alcohol Dependence

梅奥诊所酒精依赖个体化治疗中心

• 批准号: 7547818
• 负责人: DAVID A. MRAZEK
• 金额: $ 123.16万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7547818
• 关键词: Mayo; Clinic; Center; Individualized; Treatment

DESCRIPTION (provided by applicant): The Mayo Clinic Center for the Individual Treatment of Alcohol Dependence (CITA) is a P20 exploratory/ developmental alcohol research center proposal with the over-arching theme of using translational research strategies to create a new research center with the capacity to originate and conduct pharmacogenomic probe studies to differentiate treatment responses in patients with severe alcohol dependence. This new center would build upon an already existing team of researchers conducting synergistic clinical and preclinical translational research in a major academic medical center with resources already devoted to translation research and training in the provision of individualized clinical care. The importance of the goal of being able to provide individualized medical treatment for alcohol dependence has become increasingly apparent. This is specifically true related to the identification of variable responses to antidipsotropic medications. Whereas some individuals have excellent responses, there are clearly many who do not. The ability to be able to reliably differentiate those who will respond to an effective treatment has multiple benefits. The efficient identification of treatment responders would result in enormous saving of both cost and personal suffering. Another potential benefit would be the development of new medications with very targeted indications that would be uniquely helpful for selected individuals who could be identified by low cost genotyping. The feasibility of establishing this innovative approach to the study of alcohol treatment is dependent on close collaboration between the investigators of the P20 Center and the scientists who are currently working as part of the Pharmacogenomic Research Network team (PGRN) and the Advanced Genomic Technology Center (AGTC). Additionally, the broad resources of the Center for Translational Science Activities (CTSA) at the Mayo Clinic will provide a strong foundation from which to build translational research studies utilizing state-of-the-art genotyping technology. Four exploratory projects are described that foster translation from preclinical to clinical investigations. Two projects explore the relationship between genetic variation and response to acamprosate administration. The first uses a mouse model while the second is a pharmacogenomic probe study using a prospectively defined sample of subjects with alcohol dependence. The remaining two projects use magnetic resonance spectroscopy to explore the relationship between glutamate concentrations in the central nervous system and acamprosate treatment in mice and in patients treated for alcohol dependence.

描述（由申请人提供）：梅奥诊所的单个酒精依赖治疗中心（CITA）是P20探索/发育性酒精研究中心的提案，其主题是使用转化研究策略来创建一个新的研究中心，该中心具有起源和进行药物基因组基因组探针研究的能力，以区分严重酒精依赖患者的治疗反应。这个新中心将建立在已经存在的研究人员团队的基础上，该研究人员在一个主要的学术医学中心进行协同临床和临床前翻译研究，其中已经致力于翻译研究和培训，以提供个性化的临床护理。能够为酒精依赖提供个性化医疗的目标的重要性变得越来越明显。这是与鉴定对抗毒性药物的可变反应的特别相关。尽管有些人有很好的回应，但显然有很多人没有。能够可靠地区分那些将对有效治疗做出反应的人的能力具有多种好处。有效识别治疗响应者将导致大量节省成本和个人痛苦。另一个潜在的好处是开发具有非常有针对性的迹象的新药物，这对于可以通过低成本基因分型来识别的选定个人会非常有用。建立这种创新方法研究酒精治疗方法的可行性取决于P20中心的研究人员与目前作为药物基因组研究网络团队（PGRN）和高级基因组技术中心（AGTC）的一部分的科学家之间的密切合作。此外，梅奥诊所转化科学活动中心（CTSA）的广泛资源将为建立最先进的基因分型技术的转化研究提供良好的基础。描述了四个探索性项目，这些项目促进了从临床前向临床研究的翻译。两个项目探讨了遗传变异与对分支施用的反应之间的关系。第一个使用小鼠模型，而第二个是药物基因组学探针研究，使用了酗酒依赖性的受试者样本。其余的两个项目使用磁共振光谱探索中枢神经系统中谷氨酸浓度与小鼠和接受酒精依赖治疗的患者的谷氨酸浓度之间的关系。